Cite

HARVARD Citation

    Kanjanapan, Y. et al. (2019). Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities. Cancer. 125 (8), pp. 1341-1349. [Online]. 
  
Back to record